2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
James K. McCloskey, MD, discusses the efficacy of CPX-351 in FLT3-mutated acute myeloid leukemia.
James K. McCloskey, MD, chief, Leukemia Division, John Theurer Cancer Center, Hackensack Meridian Health, discusses the efficacy of CPX-351 (Vyxeos) in FLT3-mutated acute myeloid leukemia (AML).
The phase 1 V-FAST trial (NCT04075747) is meant to determine the recommended phase 2 dose of CPX-351 when administered in combination with targeted agents in previously untreated AML, specifically in patients who are fit to receive intensive chemotherapy.
When evaluating 23 patients with FLT3-mutant AML, there were the expected toxicities of induction chemotherapy, McCloskey says. However, there did not appear to be any new or unexpected toxicities, reassuring investigators, McCloskey adds. Moreover, there was a complete response rate of 82% in patients who were evaluable, McCloskey explains.
Overall, treatment with these agents appears safe and feasible with toxicities that are similar to what is known about CPX-351 with no new toxicity signals and high complete response rates, McCloskey concludes.